drugset / Trial / NCT06938204

Single Ascending Dose, Multiple Ascending Dose, Food Effect Study

NCT06938204 ↗

Phase 1 Completed 48 enrolled Innovo Therapeutics, Inc.
RandomizedSequentialDouble-blindBasic science

Summary

This is a 2-part study. Parts 1 and 2 will be a randomized, double-blind, placebo-controlled investigations of SAD (Part 1) and MAD (Part 2) of orally administered INV-101 in healthy adult subjects. Food effect will also be assessed in one cohort in Part 1.

Timeline

Start
2024-04-01
Primary completion
2024-08-09
Completion
2024-09-13

Drugs

EvaluationDrugModalityDoseRoute
Subject INV-101 Unknown — —

Indications

No indication recorded.